Unconventional Myosin-XVIIIa / CD245 (MYO18A) Antibody (PE)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Unconventional Myosin-XVIIIa / CD245 (MYO18A) Antibody (PE) is a PE-conjugated Mouse monoclonal antibody for the detection of Unconventional Myosin-XVIIIa / CD245 (MYO18A).
Documents del producto
Product specifications
Category | Primary Antibodies |
Immunogen Target | Unconventional Myosin-XVIIIa / CD245 (MYO18A) |
Host | Mouse |
Reactivity | Human |
Recommended Dilution | FCM: 10 μl/100 μl of whole blood or 106 cells. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Monoclonal |
Conjugation | PE |
Isotype | IgG1 Kappa |
Clone ID | J607 |
Purification | Purified by size exclusion chromatography. |
Size 1 | 100 tests |
Tested Applications | FCM |
Buffer | PBS pH 7.4, containing 15 mM sodium azide. |
Availability | Shipped within 5-12 working days. |
Storage | Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze. |
Dry Ice | No |
Background | Antibody anti-MYO18A |
Status | RUO |
Descripción
Related Products

MYO18A antibody
May link Golgi membranes to the cytoskeleton and participate in the tensile force required for vesicle budding from the Golgi. Thereby, may play a role in Golgi membrane trafficking and could indirectly give its flattened shape to the Golgi apparatus. Alternatively, in concert with LURAP1 and CDC42BPA/CDC42BPB, has been involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. May be involved in the maintenance of the stromal cell architectures required for cell to cell contact.
Ver Producto
MYO18A antibody
Inhibits the cytotoxic effects of TNF-alpha and overexpressed TNF receptor adapters TRADD, FADD, and RIPK1. Involved in TGF-beta1 inhibition of IkappaB-alpha expression and suppression of TNF-mediated IkappaB-alpha degradation.
Ver Producto